Presentation Description: Osteosarcoma was initially considered to be a chemo-resistant tumor.  In the early 1970s high dose Methotrexate and amputation administered alone or in combination with other agents yielded a cure rate of 40-65 percent.  This result was challenged.  In this presentation, the saga of the controversy and the final acceptance of the regimen is described.

Speaker:

Norman Jaffe, MD, Dip Paed, DSc
Professor Emeritus
The University of Texas MD Anderson Cancer Centre, Houston, TX